Methotrexate and Roxicet drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Methotrexate (methotrexate sodium) and Roxicet (acetaminophen; oxycodone hydrochloride). Common drug interactions include depression among females and neuropathy peripheral among males.

The phase IV clinical study analyzes what interactions people have when they take Methotrexate and Roxicet. It is created by eHealthMe based on reports of 48 people who take the same drugs from the FDA, and is updated regularly.

What is Methotrexate?

Methotrexate has active ingredients of methotrexate sodium. It is often used in rheumatoid arthritis. eHealthMe is studying from 604,312 Methotrexate users. Check the latest studies of Methotrexate.

What is Roxicet?

Roxicet has active ingredients of acetaminophen; oxycodone hydrochloride. It is often used in pain. eHealthMe is studying from 2,254 Roxicet users. Check the latest studies of Roxicet.



On Jul, 12, 2026

48 people who take Methotrexate and Roxicet together, and have interactions are studied.

Methotrexate and Roxicet drug interactions.

What are the common drug interactions of Methotrexate and Roxicet, by gender? *:

female:

  1. Depression
  2. Dyspepsia (indigestion)
  3. Haemorrhoids (a swollen vein or group of veins in the region of the anus)
  4. Swelling face
  5. Arthralgia (joint pain)
  6. Back pain
  7. Herpes zoster
  8. Neoplasm progression (growth of tumour)
  9. Osteolysis (dissolution of bone)
  10. Spinal osteoarthritis (joint cartilage loss in spine)

male:

  1. Neuropathy peripheral (surface nerve damage)
  2. Anxiety
  3. Cardiac failure congestive
  4. Cardio-respiratory arrest (sudden dysfunction of heart and lungs)
  5. Cardiomegaly (increased size of heart than normal)
  6. Chest pain
  7. Diabetes mellitus inadequate control
  8. Electrolyte imbalance
  9. Gait disturbance
  10. Haemorrhage (bleeding)

What are the common drug interactions of Methotrexate and Roxicet, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

  1. Deep vein thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis)
  2. Oedema peripheral (superficial swelling)
  3. Pain in extremity

30-39:

n/a

40-49:

  1. Anxiety
  2. Hypoaesthesia (reduced sense of touch or sensation)
  3. Sinus tachycardia (a heart rhythm with elevated rate of impulses originating from the sinoatrial node)
  4. Abdominal pain
  5. Neuropathy peripheral (surface nerve damage)
  6. Osteoarthritis (a joint disease caused by cartilage loss in a joint)
  7. Dysphagia (a condition in which swallowing is difficult or painful)
  8. Dyspnoea (difficult or laboured respiration)
  9. Weight decreased
  10. Abscess (pus)

50-59:

  1. Renal failure (kidney dysfunction)
  2. Stress
  3. Fatigue (feeling of tiredness)
  4. Nervous system disorder (a general class of medical conditions affecting the nervous system)
  5. Renal injury (kidney injury)
  6. Sensation of heaviness
  7. Therapeutic response decreased (less preventive response)
  8. Tubulointerstitial nephritis (a form of nephritis affecting the interstitium of the kidneys surrounding the tubules)
  9. Anxiety
  10. Depression

60+:

  1. Gait disturbance
  2. Neuropathy peripheral (surface nerve damage)
  3. Injection site erythema (redness at injection site)
  4. Injection site haemorrhage (bleeding from injection site)
  5. Injection site irritation
  6. Injection site scab
  7. Abdominal discomfort
  8. Adverse drug reaction
  9. Anaemia (lack of blood)
  10. Angioedema (rapid swelling of the dermis)

What are the existing conditions these people have? *

  1. Narcolepsy (brain's inability to regulate sleep-wake cycles normally): 14 people, 29.17%
  2. Cataplexy (loss of muscle tone accompanied by full conscious awareness): 11 people, 22.92%
  3. Neoplasm Malignant (cancer tumour): 9 people, 18.75%
  4. Osteoporosis (bones weak and more likely to break): 8 people, 16.67%
  5. Breast Cancer Metastatic: 8 people, 16.67%
  6. High Blood Pressure: 5 people, 10.42%
  7. High Blood Cholesterol: 4 people, 8.33%
  8. Stress And Anxiety: 3 people, 6.25%
  9. Nausea And Vomiting: 3 people, 6.25%
  10. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 3 people, 6.25%

* Approximation only. Some reports may have incomplete information.

Do you take Methotrexate and Roxicet?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Methotrexate and Roxicet:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Methotrexate:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Roxicet:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Methotrexate and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Roxicet and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on methotrexate sodium and acetaminophen; oxycodone hydrochloride (the active ingredients of Methotrexate and Roxicet, respectively), and Methotrexate and Roxicet (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: